Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Bio-Path Holdings ( (BPTH) ).
On June 20 and 21, 2025, Bio-Path Holdings experienced significant leadership changes with the resignation of Peter H. Nielsen from multiple executive and board roles, along with board members Heath Cleaver and Aline Sherwood. Subsequently, on June 22, 2025, Douglas P. Morris was appointed as Chairman of the Board. The company has implemented an operational pause to conserve capital, furloughing most employees while seeking additional financing. The Board is evaluating strategies due to limited capital, with potential impacts on drug development programs and the possibility of liquidation if financing is not secured.
The most recent analyst rating on (BPTH) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Bio-Path Holdings stock, see the BPTH Stock Forecast page.
Spark’s Take on BPTH Stock
According to Spark, TipRanks’ AI Analyst, BPTH is a Underperform.
Bio-Path Holdings’ stock is significantly challenged by poor financial performance, characterized by no revenue and high cash burn. The technical indicators also suggest a bearish trend. However, the promising pre-clinical results offer a glimmer of hope for future prospects. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. Overall, the stock is risky, with financial sustainability being a major concern.
To see Spark’s full report on BPTH stock, click here.
More about Bio-Path Holdings
Average Trading Volume: 31,048
Technical Sentiment Signal: Sell
Current Market Cap: $1.59M
See more data about BPTH stock on TipRanks’ Stock Analysis page.